[18] [19] Patient preferences, treatment burden, and cost are legitimate considerations
Tirzepatide Dual-Action Weight Management Tirzepatide is the active ingredient in FDA-approved dual GLP-1/GIP receptor agonist medications
This includes physical evaluations, detailed body composition analyses, and consultations focused on your dietary habits, physical activity levels, and lifestyle challenges
Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are both FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity
However, the risk increases if you are also taking insulin or a sulfonylurea (such as gliclazide)
doi: 10.1016/j.jdiacomp.2022.108332, 36